Source: Υπουργείο Υγείας (CY) Revision Year: 2022 Publisher: C.G. Papaloisou Ltd, 35 Kilkis Avenue, 2234 Cyprus
Zomig 2.5 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Round, biconvex, yellow film-coated tablets containing 2.5 mg of zolmitriptan. The tablets are intagliated with the letter ‘Z’ on one side. |
Zolmitriptan.
Each 2.5 mg film-coated tablet contains 2.5 mg zolmitriptan.
Excipients: Each 2.5 mg film-coated tablet contains 100 mg lactose.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Zolmitriptan |
Zolmitriptan has been demonstrated to be a selective agonist for the vascular human recombinant 5HT1B and 5HT1D receptor subtypes. Zolmitriptan is a high affinity 5HT1B/1D receptor agonist with modest affinity for 5HT1A receptors. |
| List of Excipients |
|---|
|
Lactose anhydrate |
Tablets of 2.5 in blister packs, containing 3 or 6 tablets.
The blister strip is polyamide Al-PVC/Al.
Not all pack sizes may be marketed.
C.G. Papaloisou Ltd, 35 Kilkis Avenue, 2234 Cyprus
Zomig 2.5 mg: 17688
13 April 1998
| Drug | Countries | |
|---|---|---|
| ZOMIG | Austria, Australia, Brazil, Canada, Cyprus, Germany, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Malta, Mexico, Netherlands, Singapore, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
